MX352599B - Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. - Google Patents
Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.Info
- Publication number
- MX352599B MX352599B MX2013012393A MX2013012393A MX352599B MX 352599 B MX352599 B MX 352599B MX 2013012393 A MX2013012393 A MX 2013012393A MX 2013012393 A MX2013012393 A MX 2013012393A MX 352599 B MX352599 B MX 352599B
- Authority
- MX
- Mexico
- Prior art keywords
- protein tyrosine
- type protein
- tyrosine phosphatase
- antibody
- human receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Mycology (AREA)
Abstract
La presente invención se refiere a un método para la producción del anticuerpo monoclonal o fragmento que incluye una región del mismo que un antígeno, caracterizado porque se une a un dominio extracelular de una proteína tirosina fosfatasa de tipo de receptor humano ??(PTPRS humano) sobre una célula dendrítica plasmacitoide que comprende las siguientes etapas: 1) administrar a un animal no humano, una célula no humana que expresa de manera exógena una proteína que incluye un dominio extracelular de PTPRS humano para inmunizar al animal con la célula; 2) seleccionar una célula productora de anticuerpo que produce un anticuerpo que se une a PTPRS humano a partir de la célula productora de anticuerpo del animal inmunizado; y 3) cultivar la célula productora de anticuerpo seleccionada en el inciso (2) y recolectar un anticuerpo que reconoce PTPRS humano a partir del cultivo y unirlo a una célula dendrítica plasmacitoide.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011101752 | 2011-04-28 | ||
| PCT/JP2012/061795 WO2012148003A1 (en) | 2011-04-28 | 2012-04-27 | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013012393A MX2013012393A (es) | 2014-04-30 |
| MX352599B true MX352599B (es) | 2017-11-30 |
Family
ID=46147004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013012393A MX352599B (es) | 2011-04-28 | 2012-04-27 | Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9803026B2 (es) |
| EP (2) | EP2702412B1 (es) |
| JP (2) | JP6001557B2 (es) |
| KR (1) | KR101873614B1 (es) |
| CN (1) | CN103703372B (es) |
| AU (2) | AU2012248158C1 (es) |
| CA (1) | CA2834243C (es) |
| ES (2) | ES2638088T3 (es) |
| HU (2) | HUE034752T2 (es) |
| IL (1) | IL229127A (es) |
| MX (1) | MX352599B (es) |
| PL (2) | PL3232202T3 (es) |
| PT (2) | PT3232202T (es) |
| RU (2) | RU2013152816A (es) |
| SG (3) | SG10202108240VA (es) |
| WO (1) | WO2012148003A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008270972B2 (en) | 2007-07-02 | 2013-10-24 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| SG10202108240VA (en) * | 2011-04-28 | 2021-09-29 | Sbi Biotech Co Ltd | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| AU2013289990B2 (en) * | 2012-07-13 | 2018-06-14 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
| EP2877494B1 (en) * | 2012-07-23 | 2020-07-15 | La Jolla Institute for Allergy and Immunology | Ptprs and proteoglycans in autoimmune disease |
| EP3102940B1 (en) * | 2014-02-04 | 2019-06-26 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| US11160873B2 (en) * | 2014-02-04 | 2021-11-02 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| CA2961374A1 (en) | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| KR20170094787A (ko) * | 2014-12-18 | 2017-08-21 | 에프. 호프만-라 로슈 아게 | Cdc 유발 항체를 측정하기 위한 검정 및 방법 |
| SG11201908744PA (en) * | 2017-03-23 | 2019-10-30 | Univ Pennsylvania | Anti-c5a antibodies and uses thereof |
| JP2020514394A (ja) * | 2017-03-24 | 2020-05-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 異常な線維芽細胞におけるプロテオグリカンの不規則性及びそれに基づく治療法 |
| US11242398B2 (en) | 2017-08-01 | 2022-02-08 | Remd Biotherapeutics, Inc. | Anti-OX40 antibodies and methods of activating OX40 |
| CN112770723B (zh) | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| CA3153638A1 (en) * | 2019-10-04 | 2021-04-08 | Albert Einstein College Of Medicine | Kir3dl3 is an inhibitory receptor of the immune system and uses thereof |
| CN114426582B (zh) * | 2022-01-07 | 2022-11-25 | 陕西脉元生物科技有限公司 | 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用 |
| CN116041526B (zh) * | 2022-11-14 | 2023-09-29 | 华中农业大学 | 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用 |
| WO2024124164A2 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7847494A (en) | 1993-10-01 | 1995-05-01 | New York University | Novel receptor-type phosphotyrosine phosphatase-sigma |
| AU2003252328A1 (en) | 2002-08-01 | 2004-02-23 | Ginkgo Biomedical Research Institute Co., Ltd. | Method of detecting mouse interferon-producing cells |
| CN1761682A (zh) * | 2003-03-14 | 2006-04-19 | 大正制药株式会社 | 单克隆抗体与产生该单克隆抗体的杂交瘤 |
| JP2007530679A (ja) | 2004-03-27 | 2007-11-01 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ | 癌治療のための組成物および方法 |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| US20070134234A1 (en) | 2005-09-29 | 2007-06-14 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| WO2009003274A1 (en) * | 2007-06-29 | 2009-01-08 | The Hospital For Sick Children | Susceptibility gene for inflammatory bowel disease |
| US20110287034A1 (en) * | 2008-11-14 | 2011-11-24 | The Brigham And Womens Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| US20120231014A1 (en) * | 2009-08-18 | 2012-09-13 | Case Western Reserve University | Neural Regeneration |
| WO2011097327A2 (en) * | 2010-02-02 | 2011-08-11 | La Jolla Institute For Allergy & Immunology | Compositions and methods of modulating receptor protein tyrosine phosphatases |
| SG10202108240VA (en) * | 2011-04-28 | 2021-09-29 | Sbi Biotech Co Ltd | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
-
2012
- 2012-04-27 SG SG10202108240VA patent/SG10202108240VA/en unknown
- 2012-04-27 PT PT171743487T patent/PT3232202T/pt unknown
- 2012-04-27 ES ES12722557.1T patent/ES2638088T3/es active Active
- 2012-04-27 RU RU2013152816/10A patent/RU2013152816A/ru not_active Application Discontinuation
- 2012-04-27 PT PT127225571T patent/PT2702412T/pt unknown
- 2012-04-27 PL PL17174348T patent/PL3232202T3/pl unknown
- 2012-04-27 WO PCT/JP2012/061795 patent/WO2012148003A1/en active Application Filing
- 2012-04-27 CA CA2834243A patent/CA2834243C/en active Active
- 2012-04-27 US US14/113,904 patent/US9803026B2/en active Active
- 2012-04-27 SG SG2013079066A patent/SG194614A1/en unknown
- 2012-04-27 ES ES17174348T patent/ES2788183T3/es active Active
- 2012-04-27 CN CN201280020580.XA patent/CN103703372B/zh active Active
- 2012-04-27 SG SG10201503257WA patent/SG10201503257WA/en unknown
- 2012-04-27 AU AU2012248158A patent/AU2012248158C1/en active Active
- 2012-04-27 PL PL12722557T patent/PL2702412T3/pl unknown
- 2012-04-27 HU HUE12722557A patent/HUE034752T2/en unknown
- 2012-04-27 RU RU2017118262A patent/RU2715642C2/ru active
- 2012-04-27 JP JP2013549652A patent/JP6001557B2/ja active Active
- 2012-04-27 MX MX2013012393A patent/MX352599B/es active IP Right Grant
- 2012-04-27 KR KR1020137028325A patent/KR101873614B1/ko active IP Right Grant
- 2012-04-27 EP EP12722557.1A patent/EP2702412B1/en active Active
- 2012-04-27 EP EP17174348.7A patent/EP3232202B1/en active Active
- 2012-04-27 HU HUE17174348A patent/HUE054211T2/hu unknown
-
2013
- 2013-10-28 IL IL229127A patent/IL229127A/en active IP Right Grant
-
2016
- 2016-09-01 JP JP2016170634A patent/JP6412072B2/ja active Active
- 2016-11-23 AU AU2016262677A patent/AU2016262677B2/en active Active
-
2017
- 2017-10-06 US US15/726,669 patent/US10730955B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX352599B (es) | Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. | |
| PH12017502161A1 (en) | Anti-cd40 antibodies and uses thereof | |
| CY1123145T1 (el) | Anti-cd40 αντισωματα | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| NI201400019A (es) | Anticuerpo anti-alfabetatcr | |
| EP3702372A3 (en) | Anti-cd40 human antibodies | |
| EA201592213A1 (ru) | Антитела антирецептор трансферрина и способы их использования | |
| CR20140146A (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| GT201300233A (es) | Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2 | |
| BR112016000666A2 (pt) | Constructos de ligação de antígeno cd3 e cd19 biespecíficos | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX2014000363A (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
| EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
| WO2013115410A3 (en) | Anti-phospholipase d4 antibody | |
| EP3029069A4 (en) | Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof | |
| EA201491107A1 (ru) | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3 | |
| PH12015501360A1 (en) | Bmp-6 antibodies | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
| GB201207155D0 (en) | Antibodies | |
| SG11201810779PA (en) | Method for screening antibody using patient-derived tumor spheroids | |
| UA111372C2 (uk) | ФРАГМЕНТ Fab' АНТИТІЛА ПРОТИ NGF ЛЮДИНИ | |
| CR20150351A (es) | Proteinas de union al antígeno bcma | |
| TH142231A (th) | แอนตี้บอดี้สำหรับรีเซพเตอร์ 3 ของปัจจัยการเจริญเติบโตของหนังกำพร้า (her3) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |